Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements. Its portfolio of brands include Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was incorporated in 2021 and is headquartered in Brentford, the United Kingdom. Haleon plc(LSE:HLN) operates independently of GSK plc as of July 18, 2022.
IPO Year: 2022
Exchange: NYSE
Website: https://www.haleon.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2024 | Buy → Neutral | Goldman | |
| 8/6/2024 | Buy | Berenberg | |
| 6/5/2024 | Buy | Berenberg | |
| 4/17/2024 | Buy | HSBC Securities | |
| 12/11/2023 | Buy | Jefferies | |
| 11/1/2023 | $9.00 | Overweight | Morgan Stanley |
| 5/24/2023 | Hold | Stifel | |
| 4/6/2023 | $10.00 | Hold → Buy | Argus |
| 4/4/2023 | Outperform | Bernstein | |
| 12/7/2022 | Equal Weight → Overweight | Barclays |
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i
Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities. The exchange offers referred to herein are being made solely pursuant to the Prospectus and related documents. The exchange offers referred to herein are not being made to holders of securities in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction. LONDON, Oct. 31, 2022 /PRNewswire/ -- Haleon plc ("Haleon
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
6-K - Haleon plc (0001900304) (Filer)
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Haleon, a global leader in consumer healthcare, has chosen Vistar Media, the leading global provider of technology solutions for out-of-home (OOH) media, as its preferred partner for programmatic OOH across all key markets. Through this partnership, Vistar will collaborate with Publicis, Haleon's media agency, to power OOH campaigns worldwide—leveraging Vistar's advanced technology to maximize impact and media efficiency. As a globally renowned leader in consumer health, Haleon's decision to select Vistar as their preferred partner underscores the strategic importance of DOOH in their media strategy. By leveraging Vistar's industry-leading dem
The new campaign features Canadian NFL Player Chase Brown of the Cincinnati Bengals MISSISSAUGA, ON, Oct. 15, 2024 /CNW/ - Today, Advil proudly announced it is the official pain relief partner of the NFL in Canada. Recognizing that tough pain can slow anyone down, this partnership highlights the fast-acting relief of Advil alongside the excitement of the NFL. The campaign features Chase Brown, the speedy running back from London, Ontario, who plays for the Cincinnati Bengals. https://www.youtube.com/watch?v=bn5jduq2qNI "Advil is excited to bring this campaign to Canadians as we continue to help them tackle their pain" said Amrita Maharajh, Senior Brand Manager, Advil. The campaign will off
LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising's supply chain of the future, today announced the launch of a new collaborative approach to supply path optimisation (SPO) for global healthcare company, Haleon. PubMatic has been selected by Haleon as a preferred supply partner to increase efficiency and streamline access to video, display, and connected TV (CTV) inventory globally, while also making media investments more sustainable. PubMatic provides transparent bidding technology and actively supports Haleon brands including Advil, Centrum, and Tums through programmatic media buys, thus maximising effici
Eroxon® is Haleon's first offering in the sexual health spaceClinical studies show Eroxon® is safe and effective in men with EDEroxon® is available now for Amazon pre-order; available on shelves and online at most major retailers in October 2024WARREN, N.J., Sept. 3, 2024 /PRNewswire/ -- Eroxon®, the first-and-only FDA cleared gel available without a prescription for the treatment of erectile dysfunction (ED), is now available for pre-order in the United States through Amazon and will be available at most major retailers in October 2024. Eroxon® is clinically proven to help me
Known for his bursts of energy on the track, the 400m hurdler is partnering with Emergen-C on its newest innovation that delivers a pop of energy and immune support anytime, anywhere – no water needed! TORONTO, Aug. 6, 2024 /CNW/ - Nobody understands the need for championship-level energy and immune support better than an international athlete! That's why Emergen-C is thrilled to announce its collaboration with celebrated hurdler, Roxroy Cato, to champion its latest innovation, Emergen-C Crystals. The partnership is a perfect synergy for the athlete known for his energetic bur
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC business In recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé India Dr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its sub
BOSTON, June 3, 2024 /PRNewswire/ -- Yellow Wood Partners LLC ("Yellow Wood"), a Boston-based private equity firm known for investing in consumer brands and companies, is pleased to announce that its portfolio company, Suave Brands Company, has successfully completed the acquisition of the ChapStick brand from Haleon (NYSE:HLN). This transaction also results in Haleon becoming a shareholder in Suave Brands Company. Suave Brands Company Chief Executive Officer, Daniel Alter, said, "As we continue to build Suave Brands Company as the top independent North American beauty & personal care company by combining the agility of a start-up with the power of market leading brands, the addition of Cha
The leader in cold sore relief will shine a light on the condition, rewarding one cold sore sufferer with the limited edition, sparkling accessory. WARREN, N.J., Feb. 6, 2024 /PRNewswire/ -- Abreva is encouraging consumers to rock their cold sores with confidence, unveiling a highly covetable, one-of-a-kind pair of diamond lips. The bejeweled piece is fashioned to destigmatize a condition that many are ashamed to discuss, let alone flaunt. In fact, 2/3 of young cold sore sufferers say their self-esteem and confidence is shaken when a cold sore strikes1. The jaw-dropping 16 car
BOSTON, Jan. 25, 2024 /PRNewswire/ -- Yellow Wood Partners ("Yellow Wood"), a Boston-based private equity firm focused on investing in consumer brands and companies, today announced that its portfolio company Suave Brands Company has signed a binding offer to acquire the ChapStick brand from Haleon (NYSE:HLN), a global leader in consumer health. The transaction is intended to close in the first half of 2024 upon completion of customary closing and regulatory approvals. ChapStick invented the lip care category in the 1880s with the launch of a now-iconic lip balm that made ChapStick a household name. For more than a century, ChapStick has added products to its portfolio with innovative new i
A third study from the COSMOS trial, COSMOS-Clinic, demonstrates consistent findings that taking Centrum Silver multivitamin daily benefits memory among older adults. WARREN, N.J., Jan. 24, 2024 /PRNewswire/ -- New study results from the COSMOS trial offers additional evidence regarding the benefit of Centrum Silver multivitamins on cognitive health in older adults. The third independent cognition trial to measure cognitive function and memory in older adults echoed previous findings of COSMOS-Mind and COSMOS-Web which all indicate that daily use of Centrum Silver versus placebo resulted in significant improvements in performance on tests measuring memory.
On Wednesday, Haleon plc (NYSE:HLN) agreed to sell its nicotine replacement therapy business outside of the U.S. to Dr. Reddy's Laboratories SA, a wholly owned subsidiary of Dr. Reddy's Laboratories Limited (NYSE:RDY) for 500 million pounds (around $632 million). The nicotine replacement therapy (NRT) portfolio consists of brands such as Nicotinell, Nicabate, Habitrol, and Thrive, which are available in gum, lozenge, and patch forms across over 30 markets. The 500 million pound consideration is structured as an upfront cash payment of 458 million pounds, with a further up to 42 million pounds deferred performance-based consideration payable during 2025 and H1 2026. The transaction
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United StatesAcquisition seen as ideal anchor to continue to build the company's global consumer healthcare OTC businessIn recent years, Dr. Reddy's has increased its presence in consumer healthcare (nutrition and OTC wellness) in markets around the world, including a recent joint venture with Nestlé IndiaDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), a global pharmaceutical company, today announced that its subsidiary Dr. Re
Sanofi SA (NASDAQ:SNY) is calling for initial bids for its $20 billion consumer health division. The French pharmaceutical giant is also considering a potential public listing. Potential suitors must submit first-round bids by mid-July, Bloomberg reports. Advent International and France’s PAI Partners both expressed interest in acquiring the division, which includes over-the-counter products such as Phytoxil cough syrups and Icy Hot pain relief gels. PAI is the sole French bidder and might need to find partners to manage the transaction’s scale. Other major firms considering bids include Blackstone Inc (NYSE:BX), Clayton Dubilier & Rice, CVC Capital Partners Plc, and TPG Inc.
GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon. Following the settlement of the placing, GSK will have fully exited its position and will no longer hold any ordinary shares in Haleon. See Also: Colgate-Palmolive Has Strong Brand-Building And Analytics-Driven Marketing Strategy, Says Analyst Following the demerger and premium listing of Haleon in July 2022, GSK initially retained a 12.94% stake in Haleon. As a result of the disposals, GSK has sold 1.19 billion shares in Haleon for cumulative gross proceeds. In October, GSK raised $1.1 billion
https://www.haleon.com/news/press-releases/corporate/2024/appointment-of-dawn-allen-as-chief-financial-officer
Argus Research analyst Taylor Conrad maintains Haleon (NYSE:HLN) with a Buy and maintains $10 price target.
Goldman downgraded Haleon plc from Buy to Neutral
Berenberg initiated coverage of Haleon plc with a rating of Buy
Berenberg initiated coverage of Haleon plc with a rating of Buy
HSBC Securities initiated coverage of Haleon plc with a rating of Buy
Jefferies resumed coverage of Haleon plc with a rating of Buy
Morgan Stanley initiated coverage of Haleon plc with a rating of Overweight and set a new price target of $9.00
Stifel initiated coverage of Haleon plc with a rating of Hold
Argus upgraded Haleon plc from Hold to Buy and set a new price target of $10.00
Bernstein initiated coverage of Haleon plc with a rating of Outperform
Barclays upgraded Haleon plc from Equal Weight to Overweight
SC 13G - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)
SC 13D/A - Haleon plc (0001900304) (Subject)